TBPH vs. SLRN, ANNX, ANRO, TVTX, TRDA, PEPG, CRBP, BMEA, MRSN, and MREO
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Acelyrin (SLRN), Annexon (ANNX), Alto Neuroscience (ANRO), Travere Therapeutics (TVTX), Entrada Therapeutics (TRDA), PepGen (PEPG), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Mersana Therapeutics (MRSN), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
Acelyrin currently has a consensus target price of $23.67, indicating a potential upside of 449.11%. Theravance Biopharma has a consensus target price of $20.50, indicating a potential upside of 118.55%. Given Theravance Biopharma's higher possible upside, research analysts plainly believe Acelyrin is more favorable than Theravance Biopharma.
87.3% of Acelyrin shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Acelyrin and Acelyrin both had 2 articles in the media. Acelyrin's average media sentiment score of 0.96 beat Theravance Biopharma's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.
Theravance Biopharma has higher revenue and earnings than Acelyrin. Theravance Biopharma is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
Acelyrin has a net margin of 0.00% compared to Acelyrin's net margin of -96.12%. Acelyrin's return on equity of -19.31% beat Theravance Biopharma's return on equity.
Theravance Biopharma received 325 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 63.38% of users gave Theravance Biopharma an outperform vote while only 56.25% of users gave Acelyrin an outperform vote.
Summary
Theravance Biopharma beats Acelyrin on 11 of the 15 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
